Pregnancy Outcome After IVF/ICSI in Endometriosis Patients Stage I and II
This study is currently recruiting participants.
Verified September 2012 by AZ Jan Palfijn Gent
Sponsor:
AZ Jan Palfijn Gent
Collaborator:
Onze Lieve Vrouw Hospital
Information provided by (Responsible Party):
Dr. Decleer Wim, AZ Jan Palfijn Gent
ClinicalTrials.gov Identifier:
NCT01682642
First received: August 23, 2012
Last updated: September 7, 2012
Last verified: September 2012
| Tracking Information | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| First Received Date ICMJE | August 23, 2012 | ||||||||
| Last Updated Date | September 7, 2012 | ||||||||
| Start Date ICMJE | March 2012 | ||||||||
| Estimated Primary Completion Date | September 2013 (final data collection date for primary outcome measure) | ||||||||
| Current Primary Outcome Measures ICMJE |
|
||||||||
| Original Primary Outcome Measures ICMJE | Same as current | ||||||||
| Change History | Complete list of historical versions of study NCT01682642 on ClinicalTrials.gov Archive Site | ||||||||
| Current Secondary Outcome Measures ICMJE |
pregnancy rate [ Time Frame: 12 weeks ] [ Designated as safety issue: No ] The number of ongoing pregnancies obtained wich still is the most important issue for the patients. |
||||||||
| Original Secondary Outcome Measures ICMJE | Same as current | ||||||||
| Current Other Outcome Measures ICMJE | Not Provided | ||||||||
| Original Other Outcome Measures ICMJE | Not Provided | ||||||||
| Descriptive Information | |||||||||
| Brief Title ICMJE | Pregnancy Outcome After IVF/ICSI in Endometriosis Patients Stage I and II | ||||||||
| Official Title ICMJE | Pregnancy Outcome After IVF/ICSI in Endometriosis Associated Tubal Factor Infertility in Endometriosis Stage I and II. Comparison of Results of IVF After Surgical Therapy Only or After Surgical Vaporisation Associated With Medical Therapy. A Prospective Randomized Study. | ||||||||
| Brief Summary | In this study of endometriosis patients we compare a common treatment of surgical therapy and medical treatment for 3 months (Zoladex)with patients receiving only surgical therapy. In both cases they immediately start IVF treatment. |
||||||||
| Detailed Description | Not Provided | ||||||||
| Study Type ICMJE | Interventional | ||||||||
| Study Phase | Phase 4 | ||||||||
| Study Design ICMJE | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
||||||||
| Condition ICMJE |
|
||||||||
| Intervention ICMJE | Drug: Zoladex
after surgical vaporization patients are treated with Zoladex for 3 months |
||||||||
| Study Arm (s) |
|
||||||||
| Publications * | Not Provided | ||||||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||
| Recruitment Information | |||||||||
| Recruitment Status ICMJE | Recruiting | ||||||||
| Estimated Enrollment ICMJE | 120 | ||||||||
| Completion Date | Not Provided | ||||||||
| Estimated Primary Completion Date | September 2013 (final data collection date for primary outcome measure) | ||||||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||||
| Gender | Female | ||||||||
| Ages | 18 Years to 38 Years | ||||||||
| Accepts Healthy Volunteers | No | ||||||||
| Contacts ICMJE |
|
||||||||
| Location Countries ICMJE | Belgium | ||||||||
| Administrative Information | |||||||||
| NCT Number ICMJE | NCT01682642 | ||||||||
| Other Study ID Numbers ICMJE | 2012-000784-25 | ||||||||
| Has Data Monitoring Committee | Yes | ||||||||
| Responsible Party | Dr. Decleer Wim, AZ Jan Palfijn Gent | ||||||||
| Study Sponsor ICMJE | AZ Jan Palfijn Gent | ||||||||
| Collaborators ICMJE | Onze Lieve Vrouw Hospital | ||||||||
| Investigators ICMJE |
|
||||||||
| Information Provided By | AZ Jan Palfijn Gent | ||||||||
| Verification Date | September 2012 | ||||||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||||||